Enrolling Clinical Studies
MAJOR DEPRESSION with DAYTIME SLEEPINESS CLINICAL TRIAL
This study will assess the efficacy of Solriamfetol in the prevention of relapse of depressive symptoms in subjects with Major Depressive Disorder with excessive daytime sleepiness symptoms.
Requirements:
-
Men or women between 18 to 65 years of age.
-
Subjects with a current major depression episode of at least 4 weeks of duration.
-
Subject should sleep at least 6 hours per night and suffer excessive daytime sleepiness.
-
Subject fall asleep while reading, watching TV, riding in the car as a passenger, during lunch.
-
Subjects with BMI between 18 and 40 kg/m2.
-
No females currently pregnant, breastfeeding, nor plans to become pregnant during the study.
-
Female patients must practice an acceptable method of birth control.
-
No subjects with schizophrenia or catatonic features, bipolar disorder, panic disorder, OCD, or PTSD.
-
No subjects with history of treatment resistance with 2 or more failed medications.
-
No subjects that attempted suicide or been hospitalized for depression during current episode.
-
No subjects with history of electroconvulsive therapy in the last 6 months.
-
No subjects with HIV, hepatitis, renal insufficiency, or unstable cardiovascular disease.
-
No subjects with prior exposure to solriamfetol/SUNOSI either through a study or prescription.
-
Subject must not be enrolled in another clinical trial or have completed a study in the last 30 days.
Study Duration:
This study has a total of 21 in-clinic visits and 14 telephone contacts in about 33 weeks of duration of the study
Compensation:
This study will pay around $100 to $150 per in-clinic visit and $25 to $75 per remote visits (telephone contact). A total of $3,250 for completing the study.